• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval.

作者信息

Hakariya H, Ozaki A, Mulinari S, Moriarty F, Tanimoto T

机构信息

Interfaculty Institute of Biochemistry, University of Tuebingen, Auf der Morgenstelle 15, Tuebingen 72076, Germany.

Institute for Pharmaceutical and Social Health Sciences, Kyoto, Japan.

出版信息

QJM. 2025 Jan 1;118(1):3-4. doi: 10.1093/qjmed/hcae115.

DOI:10.1093/qjmed/hcae115
PMID:38867701
Abstract
摘要

相似文献

1
Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval.评估获得美国食品药品监督管理局加速批准的抗癌药物适应症的撤市时间。
QJM. 2025 Jan 1;118(1):3-4. doi: 10.1093/qjmed/hcae115.
2
Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.美国国立综合癌症网络肿瘤药物治疗指南中加速批准状态、试验终点与结果及建议的特征：横断面研究
BMJ Med. 2024 Apr 5;3(1):e000802. doi: 10.1136/bmjmed-2023-000802. eCollection 2024.
3
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.加速批准的癌症药物的临床获益评估。
JAMA Intern Med. 2019 Jul 1;179(7):906-913. doi: 10.1001/jamainternmed.2019.0462.
4
Extending the US Food and Drug Administration's Postmarket Authorities.扩大美国食品和药物管理局的上市后监管权。
JAMA Health Forum. 2023 Jun 2;4(6):e231313. doi: 10.1001/jamahealthforum.2023.1313.
5
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.评估美国食品药品监督管理局（FDA）替代终点表格中所包含的替代指标背后的证据，以支持癌症药物的批准。
EClinicalMedicine. 2020 Apr 13;21:100332. doi: 10.1016/j.eclinm.2020.100332. eCollection 2020 Apr.
6
Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.近期美国医疗补助计划（Medicaid）支出与使用经美国食品药品监督管理局加速批准药物的趋势。
JAMA Health Forum. 2021 Oct 8;2(10):e213177. doi: 10.1001/jamahealthforum.2021.3177. eCollection 2021 Oct.
7
Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.分析 FDA 的加速审批计划表现 1992 年 12 月至 2021 年 12 月。
Ther Innov Regul Sci. 2022 Sep;56(5):698-703. doi: 10.1007/s43441-022-00430-z. Epub 2022 Jul 28.
8
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.美国和欧洲近期撤回的3种PARP抑制剂卵巢癌治疗适应症的监管历史：加速批准途径的经验教训
J Pharm Policy Pract. 2024 Jun 4;17(1):2351003. doi: 10.1080/20523211.2024.2351003. eCollection 2024.
9
Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.美国食品药品监督管理局批准加速批准的药物的批准前和批准后研究特征。
JAMA. 2017 Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415.
10
FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.美国食品药品监督管理局在H子部分审批中的灵活性：评估有效性证据的数量
Food Drug Law J. 2016 Aug;71(1):135-157.

引用本文的文献

1
Added Therapeutic Benefits of Top-Selling Drugs in Japan: A Cross-Sectional Study Using Health Technology Assessment.日本畅销药物的额外治疗益处：一项使用卫生技术评估的横断面研究
Clin Transl Sci. 2025 Jun;18(6):e70243. doi: 10.1111/cts.70243.
2
Japan's Conditional/Time-Limited Early Approval System in Regenerative Medicine: A Case Study of Rise and Falls of Autologous Skeletal Myoblast Sheets.日本再生医学的有条件/限时早期批准制度：以自体骨骼肌成肌细胞片的兴衰为例
Clin Pharmacol Ther. 2025 May;117(5):1171-1174. doi: 10.1002/cpt.3562. Epub 2025 Jan 14.
3
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.
美国市场撤市后日本和欧洲继续批准抗癌药物：加速批准的比较研究。
Clin Transl Sci. 2024 Jul;17(7):e13879. doi: 10.1111/cts.13879.